Tags

Type your tag names separated by a space and hit enter

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.
Curr Opin Mol Ther 2010; 12(6):755-69CO

Abstract

The inflammatory cytokine IL-1β has an essential role in the innate immune response. High levels of IL-1β have been implicated in the development of many diseases, including type 1 and 2 diabetes (T1D and T2D), rheumatoid arthritis (RA) and cardiovascular disease. XOMA is developing gevokizumab (XOMA-052), an IgG2 humanized mAb against human IL-1β, for the potential treatment of these diseases. Gevokizumab has a high affinity for IL-1β and a long t1/2, which would allow for once-monthly dosing and offer a considerable advantage for patients over agents requiring more frequent dosing. Data from preclinical studies and clinical trials suggest that gevokizumab is a potentially effective and well-tolerated treatment for the indicated diseases. At the time of publication, phase II clinical trials were ongoing in patients with T1D, T2D and RA, with the T2D trials assessing key cardiovascular markers. Following promising data from a recent pilot trial, XOMA was also planning a phase I/II trial of gevokizumab for the potential treatment of uveitis in patients with the vasculitic inflammatory disorder Behçet's disease and the autoinflammatory conditions familial cold autoinflammatory syndrome and Muckle-Wells syndrome.

Authors+Show Affiliations

NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Molecular Medicine, Wellcome Trust Brenner Building, St. James's University Hospital, Beckett Street, Leeds LS9 7TF, UK.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21154167

Citation

Geiler, Janina, and Michael F. McDermott. "Gevokizumab, an anti-IL-1β mAb for the Potential Treatment of Type 1 and 2 Diabetes, Rheumatoid Arthritis and Cardiovascular Disease." Current Opinion in Molecular Therapeutics, vol. 12, no. 6, 2010, pp. 755-69.
Geiler J, McDermott MF. Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Curr Opin Mol Ther. 2010;12(6):755-69.
Geiler, J., & McDermott, M. F. (2010). Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Current Opinion in Molecular Therapeutics, 12(6), pp. 755-69.
Geiler J, McDermott MF. Gevokizumab, an anti-IL-1β mAb for the Potential Treatment of Type 1 and 2 Diabetes, Rheumatoid Arthritis and Cardiovascular Disease. Curr Opin Mol Ther. 2010;12(6):755-69. PubMed PMID: 21154167.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. AU - Geiler,Janina, AU - McDermott,Michael F, PY - 2010/12/15/entrez PY - 2010/12/15/pubmed PY - 2011/5/20/medline SP - 755 EP - 69 JF - Current opinion in molecular therapeutics JO - Curr. Opin. Mol. Ther. VL - 12 IS - 6 N2 - The inflammatory cytokine IL-1β has an essential role in the innate immune response. High levels of IL-1β have been implicated in the development of many diseases, including type 1 and 2 diabetes (T1D and T2D), rheumatoid arthritis (RA) and cardiovascular disease. XOMA is developing gevokizumab (XOMA-052), an IgG2 humanized mAb against human IL-1β, for the potential treatment of these diseases. Gevokizumab has a high affinity for IL-1β and a long t1/2, which would allow for once-monthly dosing and offer a considerable advantage for patients over agents requiring more frequent dosing. Data from preclinical studies and clinical trials suggest that gevokizumab is a potentially effective and well-tolerated treatment for the indicated diseases. At the time of publication, phase II clinical trials were ongoing in patients with T1D, T2D and RA, with the T2D trials assessing key cardiovascular markers. Following promising data from a recent pilot trial, XOMA was also planning a phase I/II trial of gevokizumab for the potential treatment of uveitis in patients with the vasculitic inflammatory disorder Behçet's disease and the autoinflammatory conditions familial cold autoinflammatory syndrome and Muckle-Wells syndrome. SN - 2040-3445 UR - https://www.unboundmedicine.com/medline/citation/21154167/Gevokizumab,_an_anti-IL-1β_mAb_for_the_potential_treatment_of_type_1_and_2_diabetes,_rheumatoid_arthritis_and_cardiovascular_disease L2 - http://www.diseaseinfosearch.org/result/592 DB - PRIME DP - Unbound Medicine ER -